QuickLinks -- Click here to rapidly navigate through this document

Exhibit 10.98

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ISSUED WITHOUT REGISTRATION UNDER
THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER ANY STATE SECURITIES LAWS, AND
MAY NOT BE SOLD, TRANSFERRED OR PLEDGED IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL AND STATE SECURITIES LAWS OR AN
OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT THE TRANSFER IS
EXEMPT FROM REGISTRATION UNDER APPLICABLE FEDERAL AND STATE SECURITIES LAWS.

THE IMMUNE RESPONSE CORPORATION
8% CONVERTIBLE SECURED PROMISSORY NOTE

$637,189   New York, New York
July 30, 2002

        FOR the receipt of $637,189 the undersigned, The Immune Response
Corporation, a Delaware corporation (the "Issuer"), hereby unconditionally
promises to pay on the Note Maturity Date (as defined in that certain Note
Purchase Agreement, dated November 9, 2001, by and between the Purchaser, Kevin
Kimberlin Partners, L.P., a Delaware limited partnership, and the Issuer, and as
amended as of February 14, 2002 and May 3, 2002, and as further amended as of
July 11, 2002 (the "Note Purchase Agreement")) to the order of The Kimberlin
Family 1998 Irrevocable Trust (the "Purchaser"), at the office of the Purchaser
located at 535 Madison Avenue, 18th Floor, New York, New York 10022, or such
other address designated by the Purchaser, in lawful money of the United States
of America and in immediately available funds, the principal amount of (a) Six
Hundred Thirty-Seven Thousand One Hundred Eighty-Nine Dollars ($637,189) or
(b) if less as a result of any voluntary conversion(s) of this Note in part in
accordance with Section 3.4 of the Note Purchase Agreement or in part into Units
as contemplated below, the aggregate unpaid principal amount of this Note.
Subject to Section 3.4 of the Note Purchase Agreement, the Issuer further agrees
to pay interest on the unpaid principal amount outstanding hereunder from time
to time, from the date hereof, in like money, at the rate of eight (8%) percent
per annum, as and at the dates specified in Section 3.3 of the Note Purchase
Agreement.

        This Note is one of the promissory notes referred to in the Note
Purchase Agreement, and is entitled to the benefits thereof, is secured as
provided therein (and as provided in that certain Intellectual Property Security
Agreement, dated November 9, 2001, executed by the Issuer, as amended as of
February 14, 2002, and as further amended as of July 11, 2002) and is subject to
conversion as set forth therein. Notwithstanding the foregoing, up to $433,362
of this Note is convertible, at the sole option of the Purchaser, in whole or in
part, into Units (as defined in the Issuer's Definitive Proxy Statement dated
May 15, 2002, the "Proxy") rather than common stock at the Closing Price (as
defined in the Proxy), solely in the event that the Issuer is (i) able to obtain
a written confirmation from The Nasdaq Stock Market that there is an applicable
exemption to do so from all applicable subsections of the National Association
of Security Dealers, Inc. ("NASD") Rule 4350(i) or (ii) able to obtain
stockholder approval as required by NASD Rule 4350(i).

        In the event of any conflict between the Note Purchase Agreement and
this Note, the terms and provisions of the Note Purchase Agreement shall govern.

        Upon the occurrence of any one or more of the Events of Default
specified in the Note Purchase Agreement or if the Issuer is unable to obtain
any stockholder approval required under NASD Rule 4350(i) by November 30, 2002,
all amounts then remaining unpaid on this Note and/or any other Note shall
become, or may be declared to be, immediately due and payable, all as provided
in the Note Purchase Agreement. The Issuer shall use its reasonable best efforts
to obtain by November 30, 2002, any stockholder approval required under NASD
Rule 4350(i).

--------------------------------------------------------------------------------

        Subject to the provisions of the legend above, this Note is freely
transferable and assignable, in whole or in part, by the Purchaser, and such
transferee or assignee shall have the same rights hereunder as the Purchaser.
The Issuer may not assign or delegate any of its obligations under this Note
without the prior written consent of the Purchaser (or its successor, transferee
or assignee).

        All parties now and hereafter liable with respect to this Note, whether
maker, principal, surety, guarantor, endorser or otherwise, hereby waive
presentment, demand, protest and all other notices of any kind.

        Subject to Section 3.3 of the Note Purchase Agreement, the Issuer agrees
to pay all of the Purchaser's expenses, including reasonable attorneys' costs
and fees, incurred in collecting sums due under this Note.

        This Note shall be subject to prepayment only in accordance with the
terms of the Note Purchase Agreement.

        This Note shall be governed by, and construed and interpreted in
accordance with, the laws of the State of New York.

    THE IMMUNE RESPONSE CORPORATION              
 
 
By:
 
 
 
         

--------------------------------------------------------------------------------

    Name:                

--------------------------------------------------------------------------------

    Title:                

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

QuickLinks

Exhibit 10.98